| Name | Title | Contact Details |
|---|---|---|
Edward Ryan |
Sr. Dir, IT, Office of CIO | Profile |
Annlea Rumfola |
EVP, Chief Information Officer | Profile |
Heather Knight |
Chief Operating Officer | Profile |
Chris Toth |
Chief Executive Officer | Profile |
Carl Jenkins |
Associate General Counsel, Legal-Regulatory | Profile |
We focus on improving the lives of our patients with collaborative care, breakthrough research and by training tomorrow`s physicians. We are University of Minnesota Physicians, the multi-specialty group practice for the University of Minnesota Medical School faculty. As clinicians, we practice in primary care and over 100 specialty and subspecialty areas. As educators, we apply our state-of-the-art knowledge to teach and mentor future physicians. As researchers, we address critical medical problems, then translate our research findings into novel therapies to benefit patients. Our physicians practice academic medicine in an environment of inquiry and education. They work closely with other specialists across disciplines so that our patients receive comprehensive, well-coordinated care tied directly to innovations developed by our research. At UMPhysicians, every employee and physician has a role to play in fostering a culture of integrity and demonstrating our values of Service, Innovation and Respect.
CurvaFix is developing implantable products to improve fracture repair in curved bones. The company is focusing on Fragility Fractures of the Pelvis (FFP) and high-impact pelvic fractures. The CurvaFix® IM Implant is the only intramedullary device capable of following the natural bone shape and filling the space within curved bones such as the pelvis.
BIOPHILE Inc is a Charlottesville, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
STS Life Sciences Division, Ethox International is a Rush, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Valeritas is committed to developing and commercializing innovative treatment solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of Type 2 diabetes. Valeritas` portfolio is headlined by the V-Go® disposable insulin delivery device, which is being commercialized and reimbursed in a specialty pharmaceutical model and is distributed through retail pharmacy.